CATHERINE BRAUN: Open Payments
NPI 1841597077 · DALLAS, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$904 in 42 payments from 17 companies in 2025. Trend: 2023 $568 · 2024 $606 · 2025 $904
Food & beverage: $804Education: $100
| Company | Payments | Amount |
|---|---|---|
| Astellas Pharma US Inc | 7 | $233 |
| Sumitomo Pharma America, Inc. | 4 | $108 |
| Novo Nordisk Inc | 5 | $81 |
| PFIZER INC. | 4 | $77 |
| GlaxoSmithKline, LLC. | 4 | $76 |
| Amgen Inc. | 3 | $61 |
| SANOFI PASTEUR INC. | 2 | $57 |
| Lilly USA, LLC | 3 | $48 |
| AstraZeneca Pharmaceuticals LP | 2 | $29 |
| Exact Sciences Corporation | 1 | $24 |
Products named: Veozah, GEMTESA, EVENITY, FLUBLOK QUADRIVALENT NORTHERN HEMISPHERE, MOUNJARO, PREVNAR 20, Ozempic, TRELEGY ELLIPTA.
Industry payments across TX — which companies pay providers there.
